CM
APLS

Caption Management’s Apellis Pharmaceuticals APLS Stock Holding History

Caption Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Sell
63,500
-539,200
-89% -$11.6M 0.01% 753
2025
Q4 		$15.1M Buy
602,700
+2,300
+0.4% +$54K 0.1% 236
2025
Q3 		$13.6M Buy
600,400
+85,400
+17% +$1.99M 0.11% 203
2025
Q2 		$8.91M Buy
515,000
+375,000
+268% +$6.94M 0.1% 235
2025
Q1 		$3.06M Sell
140,000
-526,800
-79% -$14.6M 0.03% 545
2024
Q4 		$21.3M Buy
666,800
+76,800
+13% +$2.31M 0.2% 76
2024
Q3 		$17M Sell
590,000
-414,700
-41% -$15.4M 0.27% 85
2024
Q2 		$38.5M Buy
1,004,700
+944,700
+1,575% +$42.8M 0.59% 37
2024
Q1 		$3.53M Sell
60,000
-276,400
-82% -$17.6M 0.05% 381
2023
Q4 		$20.1M Sell
336,400
-250,800
-43% -$12.7M 0.27% 78
2023
Q3 		$22.3M Buy
587,200
+421,700
+255% +$18.5M 0.34% 60
2023
Q2 		$15.1M Sell
165,500
-385,000
-70% -$33.2M 0.27% 86
2023
Q1 		$36.3M Buy
550,500
+515,500
+1,473% +$29.7M 0.7% 24
2022
Q4 		$1.81M Sell
35,000
-30,000
-46% -$1.59M 0.03% 582
2022
Q3 		$4.44M Buy
+65,000
New +$3.85M 0.06% 384
2022
Q2 		– Sell
-65,300
Closed -$3.32M – 1419
2022
Q1 		$3.32M Buy
65,300
+35,300
+118% +$1.56M 0.04% 576
2021
Q4 		$1.42M Sell
30,000
-490,900
-94% -$19.3M 0.02% 917
2021
Q3 		$17.2M Buy
520,900
+335,900
+182% +$18.9M 0.2% 122
2021
Q2 		$11.7M Buy
185,000
+138,000
+294% +$7.12M 0.15% 164
2021
Q1 		$2.02M Buy
+47,000
New +$2.22M 0.04% 511
2020
Q4 		– Sell
-30,000
Closed -$904K – 954
2020
Q3 		$904K Buy
+30,000
New +$896K 0.02% 640
2020
Q2 		– Sell
-5,400
Closed -$144K – 919
2020
Q1 		$144K Sell
5,400
-100,000
-95% -$3.55M 0.01% 737
2019
Q4 		$3.23M Buy
+105,400
New +$2.92M 0.11% 259

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Caption Management's APLS Position: Q1 2026 in Review

Caption Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 254,563 shares — an estimated $5.49M sold.

Caption Management first reported a position in APLS in Q1 2021 and held it in 15 quarters. The position peaked at $23.5M in Q4 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Caption Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 254,563 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.49M.
  • Caption Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Caption Management's Apellis Pharmaceuticals position peaked at $23.5M in Q4 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.